News | December 30, 2022
Cipla EU to invest € 15 million in Ethris
Cipla and Ethris partner for the development of mRNA-based therapies
Cipla and Ethris partner for the development of mRNA-based therapies
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Allam was serving recently as the CEO at Public Investment Fund
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
Subscribe To Our Newsletter & Stay Updated
